JUN and acute myeloid leukemia: For example, inhibiting AP-1 activity completely blocked tumorigenesis in two different patient-derived xenograft (PDX) mouse models.2 However, the molecular details of how specific TFs contribute to the maintenance of specific AML subtypes and their interaction with genes encoding other TFs is largely unclear.